NCT02608710View on ClinicalTrials.gov

RDEA3170 PK/PD Study

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

April 30, 2016

Conditions
Gout
Interventions
DRUG

RDEA3170 4.5 mg

DRUG

RDEA3170 6 mg

DRUG

RDEA3170 12 mg

Trial Locations (1)

78744

Austin

Sponsors
All Listed Sponsors
lead

Ardea Biosciences, Inc.

INDUSTRY

NCT02608710 - RDEA3170 PK/PD Study | Biotech Hunter | Biotech Hunter